DexCom, Inc. (DXCM) Enterprise Value (EV): $26.37B
The enterprise value (EV) for DexCom, Inc. (DXCM) is $26.37B as of Tuesday, June 9, 2026.
DXCM Enterprise Value (EV) Metrics
ENTERPRISE VALUE (EV)
$26.37B
DXCM Competitors' Enterprise Value (EV)
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| DexCom, Inc. (DXCM) | — | $26.37B |
| Biogen Inc. (BIIB) | $29.39B | $29.76B |
| IQVIA Holdings Inc. (IQV) | $31.09B | $52.94B |
| Centene Corporation (CNC) | $32.69B | $21.10B |
| Veeva Systems Inc. (VEEV) | $27.37B | $32.05B |
| Zoetis Inc. (ZTS) | $34.46B | $62.97B |
| Waters Corporation (WAT) | $24.19B | $23.51B |
| Mettler-Toledo International Inc. (MTD) | $23.50B | $31.01B |
| Agilent Technologies, Inc. (A) | $38.26B | $42.98B |
| BioNTech SE (BNTX) | $21.87B | $12.18B |
Enterprise Value Calculation
Market Cap
$30.17B
Total Debt
$1.24B
Cash
$917.70M
Enterprise Value
$26.37B
EV-Based Valuation Multiples
Why use EV instead of Market Cap?
- EV accounts for debt - an acquirer must pay or assume it
- EV deducts cash - the acquirer effectively receives it
- EV enables fair comparison of companies with different capital structures
- EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral
DexCom, Inc. Enterprise Value (EV) Formula & Definition
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Enterprise Value (EV) FAQ
- What is the enterprise value (EV) for DexCom, Inc. (DXCM)?
- The enterprise value (EV) for DXCM stock is $26.37B.
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach